

Key eligibility criteria

- 18–80 years of age (inclusive)
- Moderately to severely active ulcerative colitis (UC)
- Naïve to treatment with any anti-TNF therapy
- Previous immunosuppressant/corticosteroid treatment history:
 - **US sites only:** Inadequate response, loss of response, or intolerance to prior immunosuppressant treatment
 - **Ex-US sites only:** Inadequate response, loss of response, or intolerance to prior immunosuppressant and/or corticosteroid treatment
- Evidence of UC extending a minimum of 20 cm from the anal verge
- No past or present ileostomy or colostomy
- No diagnosis of Crohn's disease.

Please consider inviting patients who fulfill the above criteria to screen for the HIBISCUS II Study.

Refer to the Study Protocol for full eligibility criteria prior to patient enrollment.